Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Phase 2/3 Study of BLU-263 (elenestinib) in Indolent Systemic Mastocytosis
2020-005173-28Phase 2Active
- Sponsor
- Blueprint Medicines
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in indolent systemic mastocytosis (ISM) and monoclonal mast cell activation syndrome (MMAS) comparing BLU-263 with Placebo (2 arms). Primary endpoint: Part 1 primary endpoint. Started Jun 2021; status: active.
02
Drugs
elenestinib
03
Conditions
indolent systemic mastocytosis (ISM)monoclonal mast cell activation syndrome (MMAS)
Beyond the preview
Go deeper on 2020-005173-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005173-28.